Product Launch (Blog)

Apr, 24 2024

Global Dengue Treatment Market Poised for Growth: Key Players and Market Dynamics

Dengue fever, caused by the dengue virus transmitted through infected mosquitoes, primarily affects regions such as Brazil, Vietnam, Philippines, India, and Indonesia. With increased healthcare spending in the Asia Pacific, particularly in India and China, significant opportunities for market growth in dengue fever treatment emerge. Meanwhile, technological advancements in North America are shaping the landscape for treatment approaches. Initiatives led by WHO and other international bodies focus on enhancing vector control, surveillance, case management, and vaccination strategies to combat dengue fever's global prevalence and address emerging vector-borne diseases comprehensively.

Global Dengue Treatment Market size was valued at USD 747.85 million in 2023 and is projected to reach USD 1,178.53 million by 2031, with a CAGR of 5.85% during the forecast period of 2024-2031.

To know more, visit

Below are the Top Dengue Treatment Companies with a Significant Market Share:




Product Portfolio

Sales Geographical Coverage



Mylan N.V.

Mylan is a global pharmaceutical company with a diverse portfolio, including products for infectious diseases. Mylan potentially contributes to the Dengue treatment market by leveraging its broad reach and experience in manufacturing

  • CIPROFLOXACIN Extended-release Tablets, USP
  • PANTOPRAZOLE SODIUM Delayed-release Tablets, USP
  • RANITIDINE Injection, USP


U.S., Europe, and Asia-Pacific

In November 2020, Viatris Inc., was launched as a combination of two Mylan N.V and Pfizer Upjohn business. This combination of the two will focus on improving patient health. Viatris Inc., has the scientific, production and distribution expertise with proven medical, regulatory, and global commercial capabilities to provide high-quality medicines to patients in more than 165 countries and territories. This launch of a new company will increase the revenue of the company in near future.


Pfizer Inc.

Pfizer is one of the largest pharmaceutical companies globally, known for its extensive research and development efforts. Pfizer's resources and expertise enable it to explore potential therapies or vaccines for Dengue, leveraging its existing infrastructure and partnerships.

  • CEFTRIAXONE, 1 g and 2 g ADD-Vantage Vials (Sandoz manufactured)
  • CEFTRIAXONE, 1 g and 2 g ADD-Vantage Vials - Novaplus (Sandoz manufactured)
  • CEFTRIAXONE, 10 g Pharmacy Bulk Package (Sandoz manufactured)
  • CIPROFLOXACIN IN 5% DEXTROSE, Flexible Plastic Container U.S

North America, South America, Europe, Asia-Pacific, Middle East and Africa

In December 2019, Pfizer Inc. foundation “Global Health Innovation” has donated to fight dengue in South East Asia with an amount of USD 100,000 to support community-based initiatives focused on combatting infectious disease through programs aimed at strengthening health systems at the community and primary care level. This will increase the company's focus on dengue treatment and research development.


Teva Pharmaceuticals USA, Inc.

Teva is a prominent generic pharmaceutical company with a wide range of products across various therapeutic areas. Its expertise in manufacturing and distribution supports the availability of affordable Dengue treatment options in regions where the disease is prevalent.

  • Acetaminophen and Codeine Phosphate Tablets, USP CIII
  • Ciprofloxacin Tablets, USP



In May 2020, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) announced that had kept an eye for the strategic focus for Japan joint venture to meet the unmet demand of the generics in Japanese Market. This will help the company to increase the market share for their generics products and will help in net sales and revenue


Perrigo Company plc

Perrigo is a leading provider of over-the-counter (OTC) healthcare products, with a focus on self-care and wellness. Perrigo's expertise in consumer healthcare contributes to the management of Dengue symptoms through the production of supportive care products such as fever reducers or hydration solutions.

  • Acetaminophen
  • Panodil
  • Children's Acetaminophen 160 mg per 5 mL Cherry Flavor
  • Children's Acetaminophen 160 mg per 5 mL Grape Flavor


North America, South America, Europe, Asia-Pacific

In December 2020, Perrigo Company plc announced that they have got the U.S. FDA approval for a generic version of Acetaminophen Injection on December 6, 2020. This will increase the market share of the company in the generic market and will contribute to the company’s future revenue.


GSK plc.

GSK a major player in the global pharmaceutical industry, with a strong focus on vaccines and infectious diseases. GSK has been involved in research and development efforts for Dengue vaccines which drives further exploration into Dengue treatment options, potentially leveraging its vaccine expertise.

  • Zantac (Ranitidine Hydrochloride)


Africa, Asia-Pacific, Middle East, Europe, and America


In December 2016, Glaxosmithkline plc, inaugurated its newest global vaccines research and development (R&D) center in Rockville, Maryland, further strengthening and expanding its vaccines presence in the U.S. The facility had 450 scientists and supporting staff and will increase the R&D exposure of the company in vaccine development.


The dengue treatment market shows promising growth prospects driven by increased healthcare spending in Asia Pacific and technological advancements in North America. Collaborative efforts led by organizations such as WHO are crucial in addressing dengue fever's global impact through enhanced vector control, surveillance, case management, and vaccination strategies. While companies such as Mylan, Pfizer, Teva, Perrigo, and GSK contribute to the broader pharmaceutical landscape, there remains a need for focused research and development efforts to meet the growing demand for dengue treatments worldwide.

Client Testimonials